Carbinoxamine Maleate

CHEMBL1200974 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
406.9 g/mol
LogP
Phase
4

The maleate salt form of carbinoxamine provides first-generation antihistamine activity, reducing symptoms of allergic rhinitis, urticaria, and other allergic conditions. Like the parent compound, it crosses the blood-brain barrier and may cause drowsiness. It is commonly found in liquid formulations intended for pediatric use.

น้ำหนักโมเลกุล

406.9000 g/mol

TPSA

100.00 Ų

กลไกการออกฤทธิ์

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O

InChI

InChI=1S/C16H19ClN2O.C4H4O4/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-10,16H,11-12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-

Molecular Formula

C20H23ClN2O5

HBD / HBA

2 / 7

พันธะที่หมุนได้

8

อะตอมหนัก

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The maleate salt form of carbinoxamine provides first-generation antihistamine activity, reducing symptoms of allergic rhinitis, urticaria, and other allergic conditions. Like the parent compound, it crosses the blood-brain barrier and may cause drowsiness. It is commonly found in liquid formulations intended for pediatric use.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Carbinoxamine Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200974. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5282409. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.